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Abstract
Activation of hepatic stellate cells (HSCs) involves the induction of ECM protein synthesis and rapid cell proliferation. Thus, agents
that interfere with either process could potentially mitigate the development of liver disease by reducing the synthesis of proteins
associated with fibrosis or by reducing the number of activated HSC. Previously, we described that the non-metabolizable amino acid
analog N-(methylamino)isobutyric acid (MeAIB) reduced hepatic collagen content of rats in a model of CCl4-induced liver injury, and in
vitro studies using CFSC-2G cells indicated that MeAIB directly reduced collagen synthesis. However, the MeAIB-mediated reduction of
hepatic collagen, in vivo, following liver injury was associated with a decrease in hepatic a-smooth muscle actin (a-SMA) which
suggested that MeAIB also inhibited the activation of HSCs. Because HSC activation is inseparable from proliferation, the purpose of this
study was to examine the effect of MeAIB treatment on the proliferation of HSCs in an in vitro model utilizing CFSC-2G cell cultures. In
these studies, MeAIB effectively inhibited the proliferation of CFSC-2G cells by interfering with the progression of the cells through the
G1-phase of the cell cycle which delayed entry into S-phase. MeAIB prevented the phosphorylation of p70S6 kinase (p70S6K) at Thr389
and reduced the phosphorylation at Thr421/Ser424. Because p70S6K is required for G1-cell cycle progression and is known to be
regulated by nutrient availability, this correlates well with MeAIB interfering with the proliferation of CFSC-2G HSCs. In addition, the
rate of protein synthesis was reduced by MeAIB treatment following mitogenic stimulation, which agrees with a p70S6K-mediated
reduction in translation. These data are consistent with MeAIB inhibiting the proliferation of CFSC-2G cells by altering the mitogen
activated pathway(s) leading to phosphorylation of p70S6K by a yet to be described mechanism.
# 2004 Elsevier Inc. All rights reserved.
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1. Introduction
Liver fibrosis is characterized by the abnormal produc-
tion of extracellular matrix (ECM) components in response
to a hepatic insult, such that excess quantities of collagens
I, III, and IV are deposited in dense bands that distort the
normal liver architecture. The preponderance of evidence
indicates that hepatic stellate cells (HSC, lipocytes, fat-
storing or Ito cells) play a central role in this process and
are a significant source of fibrillar and non-fibrillar matrix
proteins. Before liver injury, HSCs are quiescent and
produce very low levels of matrix proteins, but following
a hepatic insult HSC proliferate rapidly while increasing
the expression of a-smooth muscle actin (a-SMA) and
procollagen I in a process referred to as HSC activation. In
addition, HSC are known to be major sources of collagens
and other matrix proteins that are deposited during the
development of fibrosis. Therefore, the aberrant accumula-
tion of matrix proteins occurs as a result of an increase in
the number of HSC in addition to an increase in the
biosynthesis and secretion of matrix proteins [1–4]. As a
product of our investigations into the role of amino acid
uptake and accumulation on physiological processes of the
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cell, we have observed that inhibition of proline uptake by
the non-metabolizable analog, N-(methylamino)isobutyric
acid (MeAIB), has a profound inhibitory effect on the
production of collagen in a rat model of liver injury [5]. In
addition to reducing the hepatic collagen content, a
decrease in the expression of a-SMA in liver 1 week
following CCl4-induced liver injury indicated that MeAIB
potentially interfered with the activation of HSC. Further-
more, previous studies by our laboratory indicate that
MeAIB can inhibit the rapid proliferation of hepatic cells
following partial hepatectomy [6]. Because HSC activation
is closely coupled to HSC proliferation [1], MeAIB treat-
ment could have the additional property of interfering with
HSC activation, provided the anti-proliferative properties
of MeAIB extend to HSC.
We investigated the influence of MeAIB on the pro-
liferation of the CFSC-2G HSC line to determine if
MeAIB treatment potentially inhibits the activation pro-
cess in a well established in vitro HSC model [7,8]. We
found that MeAIB inhibits movement of CFSC-2G cells
into the S-phase of the cell cycle and that interference
with G1-cell cycle progression is where MeAIB exerts an
anti-proliferative effect. Despite no change in the phos-
phorylation of mitogen activated protein kinase (MAPK,
ERK1/2), down regulation in the phosphorylation of
p70S6 kinase (p70S6K) was observed with MeAIB treat-
ment which correlates with the inhibition of G1-cell cycle
progression. Additionally, the functional implication of
hypo-phosphorylation of p70S6K was evaluated by mea-
suring protein synthesis rate following mitogenic stimu-
lation of CFSC-2G cells. The protein synthesis rate was
reduced in a dose dependent manner by MeAIB while
protein degradation was not affected. These data have led
us to conclude that MeAIB inhibits the proliferation of
CFSC-2G cells which suggests that MeAIB may inhibit
the activation of HSC in vivo following hepatic damage or
insult.
2. Experimental procedures
2.1. Cell culture
The cell line designated CFSC-2G [7,8] was derived
from rat liver, has a phenotype similar to that of early
passage primary HSC and was kindly provided by Dr. M.
Rojkind (Albert Einstein College of Medicine, NY).
CFSC-2G cells were routinely cultured in standard
MEM formulated by combining MEM (Sigma, St. Louis,
MO, Cat No. M0268) with 1 non-essential amino acids
(Sigma, Cat No. M-7145), 10 mM HEPES (pH 7.4),
10,000 units penicillin with 10 mg streptomycin per liter
and 10% FBS (Gibco-BRL, Grand Island, NY). Incubation
conditions were at 37 8C with 5% CO2 and 95% air. Cells
were passaged weekly by dissociation in Ca2þ-free Hank’s
salt solution containing 0.25% trypsin and 0.5 mM EDTA
followed by plating a 1:4 dilution of cells onto plastic in
standard MEM containing 10% FBS. The media were
changed biweekly.
2.2. Proliferation assay
The entry of serum-starved CFSC-2G cells into the
S-phase of the cell cycle was monitored by incorporation
of 3H-thymidine into DNA following mitogenic stimula-
tion with 10% FBS. Cells were dissociated with 0.1%
trypsin/1 mM EDTA in Hank’s and were plated at 5000
cells per well in 24 well tissue culture dishes in MEM
containing 10% FBS. After 24 h of attachment and recov-
ery, the medium was aspirated and replaced with serum-
free MEM. Serum-free conditions were maintained for
72 h with the medium changed once after 48 h which
resulted in a sub-confluent cell density of 40–50%.
Mitogenic stimulation of serum-starved 2G cells was
initiated by replacement of serum-free media with MEM
containing 10% FBS. DNA synthesis was measured by
aspiration of the medium and replacement with 0.25 ml of
KRB containing 1 mM MgSO4, 0.01 mM CaCl2 and
10 mCi 3H-thymidine/ml for 60 min. Incorporation of label
into DNA was measured by aspiration of the supernatant,
solublization of the cells in 0.5 ml of 0.1N NaOH/0.1%
SDS and precipitation of the macromolecules with 5%
TCAwith the inclusion of 100 mg herring DNA as a carrier.
3H-thymidine incorporation into TCA insoluble material
was quantified by scintillization spectrophotometry and
DPM normalized to protein content.
2.3. Cell cycle analysis by flow cytometry
The movement of cells through the cell cycle was
measured by quantifying the nucleic acid content by flow
cytometry [9]. Approximately 25,000 CFSC-2G cells were
plated onto 60 mm plastic dishes in MEM containing 10%
FBS and incubated for 24 h at 37 8C. The medium was
aspirated and replaced with serum-free MEM. Serum-free
conditions were maintained for 72 h with the media chan-
ged once after 48 h which resulted in a sub-confluent cell
density of 40–50%. Mitogenic stimulation of serum-
starved 2G cells was initiated by replacement of serum-
free media with MEM containing 10% FBS. Cells were
removed from the plates with Ca2þ-free Hank’s basal salt
solution containing 0.25% trypsin and 0.5 mM EDTA and
collected by centrifugation at 600 g for 15 min. Cells
were fixed at 4 8C in 0.1% freshly made paraformaldehyde
in PBS, pH 7.4, for 30 min. Cells were then washed twice
in PBS before addition of propidium iodide (PI) reagent
(100 mM NaCl, 10 mM Tris, 10 mg/l RNAse A, 1 ml/l
Nonidet P-40 and 75 mM propidium iodide, pH 8). Cells
were incubated at room temperature for 2 h in PI reagent
before analysis by flow cytometry using a Beckman FACS
Vantage at the University of Nebraska Flow Cytometry
Core Facility.
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2.4. Measurement of protein synthesis rate
CFSC-2G cells were cultured in 24 well plates and
serum-starved as described in the proliferation assays
above. The rate at which proteins were synthesized was
measured by pulse label experiments following stimulation
with MEM containing 10% FBS and 0 or 5 mM MeAIB. At
the times indicated in the experiments, the media were
aspirated and replaced with identical media containing
20 mCi/ml 3H-leucine for 60 min at 37 8C. The media were
aspirated and the cells solublized in 1 ml of 0.1% SDS
containing 0.1 M NaOH. Half of the cell lysate was
combined with 100 mg carrier protein (BSA) and precipi-
tated with 10% TCA while the protein content of the
remainder was determined by the method of Lowery.
Precipitated protein was collected by filtration under
vacuum over glass fiber disks followed by two washes
of ice-cold 5% TCA and two washes of acetone. Radio-
activity in macromolecules was measured by scintillation
counting and normalized to protein content.
2.5. Determination of protein degradation rate
Protein degradation was measured by the efflux of
radioactivity into the medium from cells pre-labeled with
3H-leucine. CFSC-2G cells were plated at 5000 cells per
well in 24 well tissue culture dishes in MEM containing
10% FBS. After 24 h of attachment and recovery, the
medium was aspirated and replaced with serum-free
MEM. After 48 h, the medium was replaced with 1 ml
of identical serum-free medium containing 10 mCi 3H-
leucine, and the cells incubated an additional 24 h to
provide for the incorporation of label into proteins. Unin-
corporated 3H-leucine was removed from the cells by
washing with three changes of serum-free MEM for
20 min. The cells were then stimulated to proliferate by
changing the medium to MEM containing 10% FBS with 0
or 5 mM MeAIB. At the times indicated in the individual
experiments, the media were aspirated and the macromo-
lecules precipitated by the addition of TCA to 10%. The
precipitated material was removed by centrifugation,
10,000 g for 10 min, and the radioactivity in the TCA
soluble fraction determined by scintillation counting.
When indicated, inhibitors were added 2 h before the
stimulation of serum-starved cells with medium containing
10% FBS.
2.6. Western blotting
Phospho-specific antibodies for p70S6 kinase, Ser 389
or Thr 421/Ser 424, were used to evaluate the phosphor-
ylation of p70S6 kinase by standard Western blotting
(New England BioLabs, Beverly, MA). CFSC-2G cells
were cultured exactly as described for the proliferation
assay above. After stimulation with 10% FBS, the cells
were harvested at defined times by aspirating the medium
and solubilizing in a buffer containing 1% SDS, 0.1 mM
EDTA and 10 mM Tris (pH 8) followed by incubation at
80 8C for 20 min. Insoluble material was removed by
centrifugation (10 min at 10,000 g) and protein content
determined by Lowry assay. Proteins (100 mg) were sepa-
rated by denaturing SDS-PAGE and transferred to nitro-
cellulose by electro-blotting. Nitrocellulose was blocked
with 2% BSA in TBST (150 mM NaCl, 10 mM Tris,
0.02% Tween 20, pH 7.5) for 2 h followed by incubation
with the indicated antibody at 4 8C for 16–18 h. Visuali-
zation of primary antibody was with HRP-conjugated
anti-rabbit IgG and autoradiography (ECL, Amersham,
England).
2.7. Statistical analysis
Each data point represents the mean standard devia-
tion of a minimum of three determinations or the number of
replicates (n-value) indicated in the individual experi-
ments. Significance was evaluated utilizing a Student’s
t-test with P < 0:01 set as statistically significant.
3. Results
3.1. Stellate cell proliferation is inhibited by MeAIB
The proliferation of CFSC-2G cells was evaluated by
pulse labeling DNA with 3H-thymidine. As illustrated in
Fig. 1, the stimulation of serum-starved CFSC-2G cells
with 10% FBS resulted in the proliferation of the cells with
DNA synthesis detectable after 10 h and with maximal
synthesis of DNA occurring at 20 h post stimulation. The
Fig. 1. Inhibition of CFSC-2G proliferation by MeAIB treatment. CFSC-
2G cells were plated and serum-starved as described in Section 2. The cells
were subjected to mitogenic stimulation by the replacement of serum-free
medium with identical medium containing 10% FBS at time 0. MeAIB
was included in the medium at 0 (*) or 5 mM (*). The DNA synthesis
rate was measured at 0, 4, 8, 16, 20, and 24 h by pulse labeling with
3H-thymidine as described in Section 2. Data represent the mean S:D: of
three measurements (n ¼ 3) and are representative of three independent
experiments. Asterisks indicate a significant difference at the P < 0:01
level.
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rate of synthesis was reduced at 24 h. These data are
consistent with a synchronous movement of cells from a
quiescence state, presumably in the G0/1-phase of the cell
cycle, into the S-phase of the cell cycle and finally out of
S-phase. The addition of 5 mM MeAIB to the medium
significantly reduced the incorporation of thymidine into
DNA by 55 9%, 39 11%, and 15 6% at 16, 20, and
24 h following stimulation, respectively. These observa-
tions indicate that MeAIB inhibits the proliferation of
CFSC-2G cells and suggests that the entry of the cells
into the S-phase of the cell cycle is inhibited.
3.2. Cell proliferation is blocked in the G0/G1-phase
Flow cytometry of cellular DNA content was utilized for
the evaluation of the effect of MeAIB on the entry of
CFSC-2G cells into the cell cycle. Following serum star-
vation, the preponderance of CFSC-2G cells (87.6%)
contained a 2N amount of DNA indicating that the cells
were effectively arrested in the G0/1-phase of the cell cycle
as seen in Fig. 2A. Stimulation of the cells with 10% FBS
resulted in the progression of cells through the G0/1-phase,
into the S-phase of the cell cycle (Fig. 2B) and eventually
to the G2-phase (Fig. 2D). MeAIB reduced the number of
cells entering the S-phase of the cell cycle by almost 40%
as seen in Fig. 2C, which reduced the number of cells
reaching the G2-phase by 58% as seen in Fig. 2E. However,
MeAIB treatment did not completely block the entry of
CFSC-2G cell into S-phase (Fig. 2E). These data confirm
the findings obtained by 3H-thymidine incorporation and
verify that MeAIB interferes with the entry of CFSC-2G
cells into the S-phase of the cell cycle. These data are
consistent with MeAIB-mediated interference with G1-cell
cycle progression which delays the entry of CFSC-2G cells
into S-phase and subsequently reduces the number of
cells reaching the G2-phase.
3.3. Phosphorylation of p70S6K is inhibited by MeAIB
Because p70S6K is known to be regulated by amino
acids and is required for G1-progression, the phosphoryla-
tion of key regulatory residues of p70S6K was investigated
by using phospho-specific antibodies. MeAIB treatment
completely abrogated the phosphorylation of p70S6K at
Thr389, while the timing of p70S6K phosphorylation at
Thr421/Ser424 was altered as seen in Fig. 3. p70S6K
demonstrated detectable phosphorylation of Thr389 fol-
lowing stimulation with FBS at 2, 4, and 8 h, while the
inclusion of 5 mM MeAIB resulted in no detectable phos-
pho-Thr389. By comparison, phospho-Thr421/Ser424 was
detected at 2, 4, 8, and 24 h following stimulation, but
inclusion of 5 mM MeAIB resulted in detection of phos-
pho-Thr421/Ser424 at 2 and 4 h only. Because the phos-
phorylation of MAPK (ERK1/2) was not affected by
treatment with MeAIB (Fig. 3), the inhibition was reason-
ably specific for p70S6K and shows that MeAIB treatment
does not produce a general down regulation of all mitogen
activated protein kinase activities.
3.4. MeAIB inhibits protein synthesis but
not catabolism
Activated p70S6K results in the phosphorylation of the
ribosomal S6 subunit which is thought to up regulate the
translation of a family of mRNAs containing a 50 poly-
pyrimidine tract and is required for G1-cell cycle progres-
sion [10–12]. Since MeAIB inhibits the phosphorylation of
p70S6K following stimulation of CFSC-2G cells, the
functional implication of reduced activation was evaluated
by measuring protein synthesis rates. The incorporation of
3H-leucine into macromolecules was used as a measure of
protein synthesis rates which were increased from baseline
when CFSC-2G cells were exposed to medium containing
10% FBS. The addition of 0.5 to 5 mM MeAIB reduced the
incorporation of 3H-leucine into proteins in a concentration
dependent manner as illustrated in Fig. 4 which increased
with time after mitogenic stimulation. Addition of MeAIB
before the addition of FBS did not change the baseline
(time 0) protein synthesis rates indicating that only pro-
liferating cells were affected by MeAIB treatment.
MeAIB-mediated inhibition of increased protein synthesis
following mitogenic stimulation correlates well with the
observed decrease in p70S6K phosphorylation following
MeAIB treatment.
As a control, the rate of protein degradation by CFSC-
2G cells was also evaluated by measuring the efflux of
radioactivity from cellular proteins previously labeled with
3H-leucine. Addition of 5 mM MeAIB to the media during
the mitogenic stimulation of serum-starved CFSC-2G cells
did not alter the efflux of radioactivity into the medium as
seen in Fig. 5. Increasing the leucine concentration in the
medium to 2 mM produced representative results (data not
shown). Some experiments included 10 mM NH4Cl, 10 mM
N-acetyl-leu-leu-norleu-al (ALLN, Sigma, St. Louis, MO)
or N-boc-ile-glu-(O-t-butyl)-ala-leucinal (PSI, Peptides
International, Louisville, KY) to inhibit protein degrada-
tion by lysosome, Ca2þ-activated proteosome and proteo-
some activities, respectively. As illustrated in Fig. 5, the
relative strength of the inhibitors at reducing the release of
radioactivity from proteins was PSI >> ALLN > NH4Cl.
This suggests that the proteosome plays a larger role
in protein catabolism relative to the lysosome in CFSC-
2G HSCs, and that the protein synthesis rate measurements
were not confounded by alterations in the rate of protein
catabolism.
4. Discussion
MeAIB inhibits the uptake of amino acids that gain entry
into the cell via the ‘‘System A’’ amino acid transporter by
a competitive mechanism [13]; therefore, the effect of
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MeAIB treatment is a reduction in the uptake and inter-
cellular concentration of System A substrate amino acids
such as alanine, glycine and proline. Because the high
affinity, active transport of proline in most cell types is
largely due to the System A transporter activity, the effect
of MeAIB treatment on proline uptake and subsequent
intracellular concentration can be quite significant. For
example, MeAIB can essentially eliminate the active con-
centration of proline in CFSC-2G cells without effecting
the intercellular concentration of leucine [5]. While the
effect of MeAIB on the cellular concentration of other
substrate amino acids has not been evaluated in CFSC-2G
Fig. 2. Cell-cycle analysis of CFSC-2G cells. CFSC-2G cells were plated in pairs and serum-starved as described in Section 2. Cells were stimulated to
proliferate by the supplementation of the media with FBS to 10% at time 0. Cells were harvested and analyzed by FACS at 0 (panel A), 16 (panels B and C) or
24 h (panels D and E) as described in Section 2. MeAIB was included at 0 mM (panels A, B, and D) or 5 mM (panels C and E) at the time of mitogenic
stimulation. Data are composed of approximately 2 104 measurements and are representative of three independent experiments.
T.L. Freeman et al. / Biochemical Pharmacology 68 (2004) 223–230 227
cells, we hypothesize that a MeAIB-mediated reduction in
the intercellular concentration of specific amino acids
would trigger the cell’s regulatory machinery that is
responsible for evaluating adequate nutritional status prior
to cell proliferation.
The MeAIB-mediated down regulation of p70S6K phos-
phorylation state, following mitogenic stimulation of
CFSC-2G cells, supports the idea that nutritional para-
meters can regulate cell proliferation. The p70S6K is a well
known regulatory enzyme that is critical for cell cycle
progression through G1 [14] and is known to be modulated
by amino acid availability [15–17]. While leucine has been
reported as the most effective modulator of p70S6K phos-
phorylation [16–18], our data indicate the non-metaboliz-
able amino acid analog, MeAIB, is an efficient modulator
of p70S6K as well. Because the phosphorylation of
p70S6K at Thr389 is critical for kinase function and most
closely correlates with p70S6K kinase activity in vivo
[11,12], MeAIB-mediated inhibition of this site provides
a foundation on which future studies can be based. For
example, the phosphorylation of Thr229 by phosphoinosi-
tide-dependent protein kinase (PDK1) is required prior to
phosphorylation of the Ser/Thr-Pro sites in the autoinhi-
bitory domain and Thr389 in the linker domain [19] which
leads us to a testable hypothesis that MeAIB may act by
Fig. 3. Phosphorylation of p70S6K and MAPK by CFSC-2G HSCs. The phosphorylation of p70S6K (Thr389 or Thr421/424) and MAPK (ERK1/2) was
evaluated by Western blot utilizing phospho-specific antibodies as described in Section 2. Serum-starved cells were stimulated with medium containing 10%
FBS and 0 mM (lanes 1–6) or 5 mM MeAIB (lanes 7–12). Cells were harvested 0 (lanes 1 and 7), 2 (lanes 2 and 8), 4 (lanes 3 and 9), 8 (lanes 4 and 10), 24
(lanes 5 and 11) and 36 h (lanes 6 and 12) following mitogenic stimulation.
Fig. 4. Effect of MeAIB on incorporation of leucine into proteins of
proliferating cells. CFSC-2G cells were plated and serum-starved as
described in Section 2. Cells were stimulated to proliferate by the
supplementation of the media with FBS to 10% at time 0. MeAIB was
included in the medium at 0 (*), 0.5 (*), 2.5 (!) or 5 mM (5) and
protein synthesis rate determined by pulse labeling with 3H-leucine. Data
are the mean S:D: of four measurements (n ¼ 4) and are representative
of three independent experiments. Asterisks indicate a significant
difference at the P < 0:01 level.
Fig. 5. Effect MeAIB on protein catabolism. CFSC-2G cells were plated,
pre-labeled with 3H-leucine, serum-starved and washed as described in
Section 2. Cells were stimulated to proliferate by the supplementation of
the media with FBS to 10% at time 0. In the upper panel, MeAIB was
included in the medium at 0 (*) or 5 mM (*) and in the lower panel the
treatments were control (*),10 mM NH4Cl (*),10 mM N-acetyl-leu-leu-
norleu-al (!) or 10 mM N-boc-ile-glu-(O-t-butyl)-ala-leucinal (5). The
release of acid soluble radioactivity was determined as described in
Section 2. Data are the mean S:D: of four measurements (n ¼ 4) and are
representative of three independent experiments. Asterisks indicate a
significant difference at the P < 0:01 level.
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interfering with the mitogen activated pathways responsi-
ble for the activation of PDK1, such as reduced PI3 kinase
activity. Alternatively, MeAIB could inhibit the phosphor-
ylation of Thr389 by interfering with the activation of a yet
to be described kinase responsible for the direct phosphor-
ylation of this site. Unfortunately, the reduced phosphor-
ylation at Thr421/Ser424 following MeAIB treatment is
complicated due to the influence of previously phosphory-
lated residues modifying subsequent phosphorylation of
other sites, but the growth factor activation of MAPK can
be eliminated because MeAIB did not alter the phosphor-
ylation of ERK1/2. These studies provide a framework for
the logical determination of the mechanism by which
MeAIB exerts an anti-proliferative effect on CFSC-2G
HSCs, and the G1 blockade of cell cycle progression by
MeAIB is consistent with down regulation of p70S6K
phosphorylation.
Interestingly, rapamycin, an inhibitor of p70S6K phos-
phorylation, has been reported to inhibit stellate cell pro-
liferation and limits fibrogenesis in a rat model of liver
fibrosis (Zhu et al. 1999) which suggests that reduced
activation of p70S6K is a mechanism rapamycin shares
with MeAIB. Rapamycin inhibits phosphorylation of
p70S6K by interaction with the target of rapamycin
(mTOR, FRAP). mTOR is a member of the ATM-related
kinase family and is known to be activated by the insulin
receptor signaling cascade, PI3 kinase and protein kinase B
(PKB, Akt) [20–22]. Also, mTOR activation is distinct
from the Ras/MAP kinase cascade components [11], and
mTOR can be activated independently of insulin by amino
acids through a nutrient signaling pathway [23,24]. Given
the similarity between the effect of rapamycin and MeAIB
on the deposition of collagen following experimental
liver injury and the shared inhibition of p70S6K, the
role of p70S6K activation in abnormal HSC function is
emphasized.
In conclusion, we report that MeAIB inhibits the pro-
liferation of CFSC-2G cells by retarding the movement of
the cells into the S-phase of the cell cycle. The MeAIB-
mediated interference in proliferation was accompanied by
an alteration in P70S6K phosphorylation and by a reduc-
tion in the rate of protein synthesis following mitogenic
stimulation. Protein catabolism and the phosphorylation
of MAPK were not effected by MeAIB treatment.
These observations are consistent with MeAIB treatment
producing an anti-proliferative response sometime in the
G0/G1- to S-phase transition of the cell cycle.
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